Company / Current Liabilities
Travere Therapeutics, Inc. Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$159.9M
FY2025
5-year range
$124.1M / $200.8M
FY2021-FY2025
Trend
-20.3%
vs FY2024
Sector context
#66 of 213
Health Care
What the data says
At $160M, Travere Therapeutics, Inc.'s current liabilities ranks #148 of 213 in the Health Care sector. Current Liabilities has fluctuated over the past 10 years, ranging from $83M in FY2016 to $201M in FY2024.
Based on SEC 10-K filings.
$160M in FY2025 with a 5-year CAGR of +11.5%.
Improved from $178M to $160M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +4.0%
- 5-Year CAGR
- +11.5%
- 10-Year CAGR
- -
Sector benchmark
#148 of 213 in Health CareTop 69% of 213This company $159.9M Sector average $1.6B
▼
-89.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +11.5%, indicating consistent growth.
- In FY2025, current liabilities decreased 20.3% year-over-year.
- Ranks #66 out of 213 companies in the Health Care sector.
- Peak current liabilities was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $159.9M | -20.3% |
| FY2024 | $200.8M | +12.8% |
| FY2023 | $177.9M | +25.1% |
| FY2022 | $142.2M | +14.6% |
| FY2021 | $124.1M | +33.9% |
| FY2020 | $92.7M | -2.9% |
| FY2019 | $95.4M | -8.8% |
| FY2018 | $104.6M | +22.1% |
| FY2017 | $85.7M | +2.9% |
| FY2016 | $83.3M | -4.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026